Page 13 - Tim Walbert News Today

Horizon Horizon in December announced it would delay new patients from starting Tepezza treatment to conserve supply for existing users.  Invoking the Defense Production Act is helping increase supply of badly needed COVID-19 vaccines, bringing the U.S. one step closer to ending the pandemic—but as one local drug company has learned, theres a catch. The government mandate to prioritize vaccine production at a biologics manufacturing facility has led to a shortage of Horizon Therapeutics top-...

Listen • 3:29 In a February visit to Pfizers Kalamazoo, Mich., manufacturing complex, President Biden said the administration had "used the Defense Production Act to speed up the supply chain for ... key equipment, like fill pumps and filters, which has already helped increase vaccine production." In the run-up to President Bidens promise on March 2 that there would be enough COVID-19 vaccines for every adult in the United States by the end of May, he talked up a Korean Wa...

Posted on 7398 Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized as one of the Best Workplaces in Ireland 2021 by Great Place to Work Ireland, ranking No. 12 in the small company category. This is the second year that Horizon has been named to the list. “We are honored to be named a Great Place to Work in Ireland,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Thi...

In the 16th and final clickbait ariticle we mined out of this AEW media call, Cody Rhodes talks marathon wrestling tapings and how to make them not suck.

Horizon Therapeutics (HZNP) Stock Hits New 52-Week High on Solid Q4 Results Horizon Therapeutics PLC (NASDAQ:HZNP) was founded in 2008 with a handful of employees and extremely limited resources. The biopharmaceutical company went public in 2011 by pricing 5.5 million shares of its common stock at $9 each share. Since then, its share price has climbed more than 900 percent. Today, Horizon’s product lineup includes some critical drugs such as Tepezza for treating thyroid eye disease (TED) and...

Horizon Therapeutics to acquire Viela Bio for $3bn Horizon Therapeutics will acquire Viela Bio, helping expand its pipeline for long term growth. Through the acquisition, Dublin-headquartered Horizon Therapeutics will grow its rare disease medicine portfolio, gaining Uplizna (inebilizumab-cdon), the first and only FDA-approved B-cell-depleting humanized monoclonal antibody for the treatment of eye disease neuromyelitis optica spectrum disorder (NMOSD)  Viela Bio �...

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition Vielas portfolio of assets includes FDA-approved NMOSD therapy Uplizna Horizon Therapeutics has entered into a definitive agreement to acquire Viela Bio for $3bn, in an effort to strengthen its rare disease portfolio. Viela Bio spun out of AstraZeneca’s Medimmune biologics unit in 2018 with six molecules and $250m in funding from a number of investors. Currently, Viela has one US Food and Drug Administration (FDA) approv...

By Reuters Staff 2 Min Read (Reuters) -Horizon Therapeutics Plc on Monday agreed to buy Viela Bio Inc for about $3.05 billion in a move to expand its rare-disease portfolio. Viela’s only approved drug, Uplizna, is used to treat a rare, severe, neuroinflammatory disease named neuromyelitis optica spectrum disorder that attacks the optic nerve spinal cord and brain stem. “This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to ac...

UPDATE: Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the first quarter. “Adding Viela’s research and clinical development capabilities along with its deep, mid-stage biologics pipeline to our seasoned R&D and commercial teams, advances our transformation to an innov...

Dive Brief: Horizon Therapeutics has agreed to acquire Viela Bio, a spinout of AstraZeneca, in a deal that values the Maryland-based biotech at roughly $3 billion. Horizon will pay $53 per share for Viela, which in June won U.S. approval for Uplizna, a treatment for the rare autoimmune disease neuromyelitis optica spectrum disorder, or NMOSD. The price represents a roughly 53% premium for Viela, whose drug competes for market share with medicines from Roche and Alexion Pharmaceuticals.   The ...